- Home
- Publications
- Publication Search
- Publication Details
Title
Treating cancer with selective CDK4/6 inhibitors
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 13, Issue 7, Pages 417-430
Publisher
Springer Nature
Online
2016-03-31
DOI
10.1038/nrclinonc.2016.26
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
- (2017) Pamela N. Munster et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy
- (2016) Jonathan W. Goldman et al. Clinical Lung Cancer
- 86O * PI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing apoptosis
- (2015) M. T. Herrera-Abreu et al. ANNALS OF ONCOLOGY
- Abstract P5-10-06: Risk of recurrence estimates with IHC4 are tolerant of variations in staining and scoring
- (2015) Andrew Dodson et al. CANCER RESEARCH
- Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer
- (2015) Sara M Tolaney et al. CANCER RESEARCH
- Abstract OT1-1-07: A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)
- (2015) Antonio Llombart et al. CANCER RESEARCH
- Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
- (2015) E. K. Ziemke et al. CLINICAL CANCER RESEARCH
- CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
- (2015) M. E. Olanich et al. CLINICAL CANCER RESEARCH
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Treatment Selection and Outcomes in Early-Stage Classical Hodgkin Lymphoma: Analysis of the National Cancer Data Base
- (2015) Adam J. Olszewski et al. JOURNAL OF CLINICAL ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
- (2015) Ruben Niesvizky et al. LEUKEMIA & LYMPHOMA
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
- (2015) Amita Patnaik et al. CANCER RESEARCH
- Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors
- (2014) David J. Vaughn et al. CANCER
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
- (2014) A. M. Heilmann et al. CANCER RESEARCH
- LINE-1 Hypomethylation, DNA Copy Number Alterations, andCDK6Amplification in Esophageal Squamous Cell Carcinoma
- (2014) Yoshifumi Baba et al. CLINICAL CANCER RESEARCH
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
- (2014) S. C. Tate et al. CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
- (2014) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Solidifying Liquid Biopsies: Can Circulating Tumor Cell Monitoring Guide Treatment Selection in Breast Cancer?
- (2014) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.
- (2014) K. E. Parrish et al. MOLECULAR CANCER THERAPEUTICS
- Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer.
- (2014) S. Kim et al. MOLECULAR CANCER THERAPEUTICS
- AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
- (2014) C. Li et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
- (2014) Y.-X. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery
- (2014) Cheng-Qiong Mao et al. MOLECULAR THERAPY
- Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
- (2014) Gaëlle Mariaule et al. MOLECULES
- PD0332991 (Palbociclib) for treatment of pediatric intracranial growing teratoma syndrome
- (2014) Kris Ann P. Schultz et al. PEDIATRIC BLOOD & CANCER
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- Translocation t(2;7)(p11;q21) associated with the CDK6/IGK rearrangement is a rare but recurrent abnormality in B-cell lymphoproliferative malignancies
- (2014) Nathalie Douet-Guilbert et al. Cancer Genetics
- The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit
- (2013) Sabrina L. Spencer et al. CELL
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Induction of prolonged early G1arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1
- (2013) David Chiron et al. CELL CYCLE
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations
- (2013) Meriem Chraybi et al. HUMAN PATHOLOGY
- Bisphosphonate-Related Osteonecrosis of Jaw in the Adjuvant Breast Cancer Setting: Risks and Perspective
- (2013) Charles L. Shapiro JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
- (2013) Mark A. Dickson et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
- (2013) A. D. Leo et al. JNCI-Journal of the National Cancer Institute
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Targeting cell cycle and hormone receptor pathways in cancer
- (2013) C E S Comstock et al. ONCOGENE
- PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
- (2013) Kelly L. Barton et al. PLoS One
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
- (2013) A. Sottoriva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- The Requirement for Cyclin D Function in Tumor Maintenance
- (2012) Yoon Jong Choi et al. CANCER CELL
- Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
- (2012) Catherine M. Sawai et al. CANCER CELL
- The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
- (2012) J. J. Luke et al. CLINICAL CANCER RESEARCH
- Sequencing of t(2;7) Translocations Reveals a Consistent Breakpoint Linking CDK6 to the IGK Locus in Indolent B-Cell Neoplasia
- (2012) Edward P.K. Parker et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts.
- (2012) C. Sanchez-Martinez et al. MOLECULAR CANCER THERAPEUTICS
- Cdk4/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
- (2012) F. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
- (2012) L. Cen et al. NEURO-ONCOLOGY
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma
- (2011) A. Ismail et al. CLINICAL CANCER RESEARCH
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Molecular characterization of a t(2;7) translocation linking CDK6 to the IGK locus in CD5− monoclonal B-cell lymphocytosis
- (2011) Edward Parker et al. Cancer Genetics
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- RB-pathway disruption in breast cancer
- (2010) Adam Ertel et al. CELL CYCLE
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
- (2010) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells
- (2010) Dayana B. Rivadeneira et al. GASTROENTEROLOGY
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
- (2010) Jordi Barretina et al. NATURE GENETICS
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
- (2009) D. Rathkopf et al. CLINICAL CANCER RESEARCH
- Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas
- (2009) A. Italiano et al. CLINICAL CANCER RESEARCH
- Cell cycle kinases as therapeutic targets for cancer
- (2009) Silvia Lapenna et al. NATURE REVIEWS DRUG DISCOVERY
- Treatment of Growing Teratoma Syndrome
- (2009) David J. Vaughn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
- (2008) E. Menu et al. CANCER RESEARCH
- HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon
- (2008) Antoine Italiano et al. INTERNATIONAL JOURNAL OF CANCER
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
- (2008) Ron Firestein et al. NATURE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now